Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.

导出 LinkOut

翻译打印收藏纠错

作者： Mark M,Awad ^[1] ; Yvan,Le Bruchec ^[2] ; Brian,Lu ^[2] ; Jason,Ye ^[3] ; Julie Ann,Miller ^[2] ; Patrick H,Lizotte ^[4] ; Megan E,Cavanaugh ^[4] ; Amanda J,Rode ^[4] ; Calin Dan,Dumitru ^[2] ; Alexander,Spira ^[5]

作者单位： Lowe Center for Thoracic Oncology and Dana-Farber Cancer Institute, Boston, MA, United States. ^[1] Bristol Myers Squibb, Princeton, NJ, United States. ^[2] Acetylon Pharmaceuticals, Inc, Boston, MA, United States. ^[3] Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States. ^[4] Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA, United States. ^[5]

关键词 ACY-241 HDAC6 citarinostat nivolumab non-small cell lung cancer

DOI 10.3389/fonc.2022.889996

PMID 35747830

发布时间 2022-06-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2022年12卷

889996页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除